VivoSeq
Oncology

Ewing Sarcoma

58

Pipeline Programs

13

Active Trials

33

Companies Involved

Ewing sarcoma is a moderately active landscape with 58 programs across 33 companies. The most active players are Jazz Pharmaceuticals, Incyte, Rabi Hanna. 2 therapies are approved with 14 more in late-stage development.

Pipeline Metrics

Competitive Density

63/100

Pipeline Velocity

15/100

Mech. Concentration

15/100

Completion Rate

61/100

Attrition Rate

21/100

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Programs by Phase

Modality Breakdown

91%

Small molecule

60 of 66 classified programs — the dominant modality here.

9%ALL OTHERSMonoclonal antibody46%Protein / enzyme12%Cell therapy12%

Small molecule leads; the ring shows all 66 classified programs, each share of the total. Modality classified for 99% of 69 pipeline programs.

Trial Status

34

clinical trials

Completed11 · 32%
Recruiting8 · 24%
Active, not recruiting4 · 12%
Terminated4 · 12%
Withdrawn3 · 9%
Unknown status2 · 6%
Other2 · 6%

Trial Activity

34 trials

Page 1 of 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)